Skip to content
Open access

Targeting MMGT1 enhances immunotherapy efficacy in triple-negative breast cancer.

Oct 2026 · Cell Reports Medicine · pp. 103120 · 0 citations · 28 references
Medicine

TL;DR

A critical role is revealed for MMGT1 in shaping the TNBC immune microenvironment and targeting MMGT1 represents a promising strategy to improve anti-PD-1 immunotherapy outcomes, suggesting that targeting MMGT1 represents a promising strategy to improve anti-PD-1 immunotherapy outcomes.

Abstract

The role of senescent tumor cells in modulating the immune microenvironment and influencing immunotherapy efficacy remains poorly understood. In this study, we investigate the function of the senescence-associated gene membrane magnesium transporter 1 (MMGT1) in triple-negative breast cancer (TNBC) immunotherapy. MMGT1 is upregulated in TNBC and correlates with poor prognosis. Mammary gland-specific knockout of Mmgt1 significantly impedes tumor growth. Mechanistically, MMGT1 promotes lipid metabolism by facilitating translocation of the SCAP-SREBP1 complex to the Golgi apparatus, thereby suppressing cellular senescence. Notably, senescent TNBC cells enhance CD8+ T cell proliferation and cytotoxicity through CCL20 secretion. Furthermore, a positive feedback loop exists between MMGT1 and SREBP1. In vivo, AZ191 downregulates MMGT1 expression, which suppresses tumor growth and enhances the efficacy of anti-PD-1 therapy. Collectively, these findings reveal a critical role for MMGT1 in shaping the TNBC immune microenvironment and suggest that targeting MMGT1 represents a promising strategy to improve anti-PD-1 immunotherapy outcomes.

Read PDF

Similar papers

Oct 2026

Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.

Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.

Y. Senent, R. Manguso · 0 citations
Open access Sep 2026

p38α orchestrates BRAFV600E-melanoma progression and immunotherapy response via tumor fitness and immune microenvironment modulation

It is reported that, in an UVB induced Braf V600E-mutated spontaneous mouse melanoma model, p38α contributes to tumor fitness and anti-tumor immune responses, showing that p38α inhibition sensitizes tumors to anti-PD1.

Paula Granado-Martínez, K. McGrail, Roberto Orsenigo et al. · 0 citations
#protein folding Open access Oct 2026

Targeting ERO1α triggers tumor immunosurveillance in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) remains a highly aggressive malignancy with limited responsiveness to immune checkpoint blockade. Here, we identify endoplasmic reticulum oxidoreductase 1 alpha (ERO1α; ERO1A), a key regulator of oxidative protein folding, as a determinant of tumor immunogenicity and immunotherapy r...

Alessandro Cherubini, E. Varone, Sara Irene Malandrin et al. · 0 citations
Open access Sep 2026

RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses

The results suggest that RAMP3 contributed to the establishment of an immunosuppressive TME and integration with human clinical datasets supports further investigation of RAMP3 as a potential therapeutic target for overcoming resistance to immune checkpoint therapy in breast cancer.

Yan Zhang, Megumu Tanaka, Takayuki Sakurai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.